Jump to any asset
849 assets, updated daily
Vertex Pharmaceuticals Incorporated Common Stock vs Regeneron Pharmaceuticals
VRTX
Vertex Pharmaceuticals Incorporated Common Stock NASDAQ
$526.19
▲ 0.73%
VS
Comparative Analysis
Regeneron Pharmaceuticals (REGN) wins this head-to-head comparison, driven by superior recent earnings performance and stronger revenue growth. While both Vertex Pharmaceuticals (VRTX) and Regeneron operate in the biotechnology sector, Regeneron demonstrates a more compelling growth profile. Its recent earnings have significantly exceeded estimates, indicating strong operational execution and market reception for its products. Vertex, despite a solid market position, shows a less consistent earnings beat rate and slower revenue expansion. Regeneron's valuation, while not as cheap as Vertex on a P/E basis, is justified by its higher growth trajectory. The company's ability to consistently deliver strong earnings surprises suggests a more dynamic business model capable of outperforming expectations. Vertex's valuation appears to price in more modest growth, making Regeneron the more attractive option for investors seeking growth in the near to medium term.
Key Differentiator
Regeneron Pharmaceuticals (REGN) stands out due to its exceptional recent earnings performance, significantly outperforming analyst estimates in its latest quarter. This demonstrates a powerful ability to generate upside surprises, suggesting strong underlying business momentum and effective execution. While Vertex Pharmaceuticals (VRTX) maintains strong profitability and a solid analyst following, its recent earnings have been less consistent, with a slight miss in the latest report. REGN's ability to deliver such a substantial beat indicates a more dynamic growth engine currently at act, making it the more compelling choice for growth-oriented investors.
Joint Outlook
Regeneron Pharmaceuticals (REGN) is expected to maintain its growth trajectory, supported by strong product demand and a history of exceeding earnings expectations. The company's ability to deliver significant positive surprises suggests potential for continued outperformance, especially if pipeline developments are favorable. Vertex Pharmaceuticals (VRTX) faces a more moderate outlook, with its higher valuation and strong profitability suggesting a more mature growth phase. While its consistent performance is a positive, the company may not offer the same level of explosive growth as REGN. Investors should watch for key pipeline advancements and competitive pressures in VRTX's core therapeutic areas.
Price Analysis Comparison
Valuation Metrics
| Metric | VRTX | REGN |
|---|---|---|
| P/E Ratio | 30.04 | 19.70 |
| Market Cap | 133.37B | 81.13B |
| Price/Sales | 10.40 | 5.28 |
| Price/Book | 6.46 | 2.52 |
| EV/EBITDA | 24.51 | 15.78 |
| Dividend Yield | N/A | 0.47% |
Regeneron Pharmaceuticals (REGN) trades at a P/E ratio of 19.7, which is considerably lower than Vertex Pharmaceuticals (VRTX) P/E of 30.0. This suggests REGN is more attractively valued on a traditional earnings multiple basis. However, VRTX's higher P/E is accompanied by a higher net profit margin of 35% compared to REGN's 27.87%. VRTX also boasts a higher return on equity at 23.54% versus REGN's 14.04%. Despite the higher P/E, VRTX's profitability metrics are stronger, indicating efficient capital utilization and earnings generation relative to its equity base.
Profitability & Efficiency
| Metric | VRTX | REGN |
|---|---|---|
| Rev. Growth (Qtly) | 12.50% | 16.70% |
| Profit Margin | 35.00% | 27.87% |
| Return on Equity | 23.54% | 14.04% |
| Return on Assets | 11.93% | 6.53% |
| Debt/Equity | 9.77 | 8.54 |
Vertex Pharmaceuticals (VRTX) exhibits superior profitability metrics, boasting a net profit margin of 35% and a return on equity of 23.54%. This indicates VRTX is more effective at converting revenue into profit and generating returns for shareholders. Regeneron Pharmaceuticals (REGN) follows with a net profit margin of 27.87% and a return on equity of 14.04%. While these figures are lower than VRTX's, they still represent solid profitability within the biotechnology sector. REGN's return on assets at 6.53% is also lower than VRTX's 11.93%.
Earnings Reality Check
VRTX
Last 4 Qs: VRTX beat estimates 2x out of 4. Fell 2x after beats. (Sell the news?)
REGN
Last 4 Qs: REGN beat estimates 3x out of 4. Rose 2x after beats.
Technical Indicators
| Indicator | VRTX | REGN |
|---|---|---|
| RSI (14) | 36.10 | 35.08 |
| 50-Day MA | $514.31 | $776.79 |
| 200-Day MA | $471.85 | $735.69 |
Regeneron Pharmaceuticals (REGN) is currently showing weaker technical signals, with an RSI of 35.08 and a MACD of 1.88, indicating bearish momentum. Its price is trading below its 20-day EMA ($796.38) and is closer to its 52-week low ($541) than its high ($859.34). Vertex Pharmaceuticals (VRTX) also displays bearish technicals, with an RSI of 36.1 and a MACD of -1.24. However, VRTX's price is trading above its 20-day EMA ($522.03) and is closer to its 52-week high ($560.25) than its low ($377.02). Both stocks are trading below their 50-day and 200-day moving averages, suggesting broader downtrends.
AI Analyst Sentiment
Technical rating: based on current price action versus moving averages and momentum. This measures short-term chart trend, not analyst opinion or company fundamentals.
VRTX
Technical Score: 59/100
REGN
Technical Score: 68/100
Analyst sentiment for Regeneron Pharmaceuticals (REGN) is predominantly positive, with 4 Strong Buys, 14 Buys, and 9 Holds among 28 analysts, and a median target price of $854, suggesting significant upside potential from its current price. Vertex Pharmaceuticals (VRTX) also garners strong analyst support, with 6 Strong Buys, 19 Buys, and 4 Holds from 31 analysts, and a median target price of $575. While both stocks have positive analyst ratings, REGN's higher proportion of 'Strong Buy' ratings and a more substantial price target relative to its current trading level suggest slightly more bullish conviction from the analyst community.
Risk Stratification
| Metric | VRTX | REGN |
|---|---|---|
| Beta (Volatility) | 0.32 | 0.19 |
| Sharpe Ratio | 0.13 | -0.34 |
Regeneron Pharmaceuticals (REGN) faces risks related to the competition in the biotechnology sector and the potential for pipeline failures or slower-than-expected drug commercialization. Its significant earnings beat in the recent quarter, while positive, could also set a high bar for future performance, increasing the risk of future misses. Vertex Pharmaceuticals (VRTX) is exposed to risks associated with its reliance on a few key therapies and the potential for regulatory hurdles or patent expirations. Its mixed earnings performance suggests potential challenges in consistently meeting market expectations, which could lead to increased stock volatility. The company's higher P/E ratio also implies a greater sensitivity to any negative news or performance shortfalls.
Comparative ProTips
- Consider REGN for its recent earnings momentum, but monitor its ability to sustain these beats.
- VRTX offers strong profitability and a lower valuation multiple, making it a potentially stable, albeit slower-growth, investment.
- Both stocks are trading below key moving averages, suggesting a cautious approach might be warranted until clearer uptrends emerge.
Monte Carlo Projection (10yr)
Actionable Trade Plans
Compare entry, exit, and risk management levels for both assets
Select Your Trade Bias
Risk Tolerance
Conservative
3%
Aggressive
Portfolio Value
$
✎
Position Size: $200 - $300 per asset
VRTX
Current: $526.19
ENTRY ZONES
Conservative
$499.88
Aggressive
$526.19
RISK MANAGEMENT
STOP LOSS
$484.88
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$524.87
+10%
$549.87
+15%
$574.86
REGN
Current: $788.04
ENTRY ZONES
Conservative
$748.64
Aggressive
$788.04
RISK MANAGEMENT
STOP LOSS
$726.18
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$786.07
+10%
$823.50
+15%
$860.93
Calculate Your Trade
Disclaimer
This comparison involves assets with varying risk profiles. The content is for educational purposes only. Identifying the stronger asset is based on relative strength (RS) and technical convergence. Past correlation does not guarantee future lockstep movement. Trading involves risk of loss. Note: The AI favored REGN based on growth trajectory. This is valid for the specified timeframe only.
Frequently Asked Questions
Which is a better buy, VRTX or REGN?+
REGN is a better buy due to its superior recent earnings performance and stronger revenue growth. While VRTX has better profitability metrics, REGN's ability to consistently beat earnings estimates suggests a more dynamic growth trajectory.
What are the key risks for VRTX vs REGN?+
VRTX faces risks from reliance on key therapies and potential patent expirations, while REGN's risks include pipeline failures and the challenge of maintaining its recent strong earnings momentum against high expectations.
How do VRTX and REGN compare on valuation?+
REGN trades at a lower P/E ratio (19.7) than VRTX (30.0), suggesting REGN is more attractively valued on this metric. However, VRTX offers higher profitability margins and return on equity.
Which stock has better earnings quality?+
REGN demonstrated significantly better earnings quality in its most recent quarter, beating estimates by nearly 40%, whereas VRTX slightly missed its estimate. REGN's consistency in positive surprises is a key differentiator.
What is the dividend yield for VRTX and REGN?+
REGN offers a small dividend yield of approximately 0.47%.
How do their technicals compare?+
Both stocks show bearish technicals with low RSI values. VRTX is trading above its 20-day EMA and closer to its 52-week high, while REGN is trading below its 20-day EMA and closer to its 52-week low.
What is the analyst sentiment for each stock?+
Both stocks have strong analyst ratings, but REGN shows a slightly higher proportion of 'Strong Buy' ratings and a more substantial price target relative to its current price, indicating slightly more bullish conviction.